These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9572062)

  • 1. AUC and cmax are not sufficient to prove bioequivalence.
    Rescigno A; Powers JD
    Pharmacol Res; 1998 Feb; 37(2):93-5. PubMed ID: 9572062
    [No Abstract]   [Full Text] [Related]  

  • 2. Is Cmax/AUC useful for bioequivalence testing?
    Rostami-Hodjegan A; Tucker GT
    J Pharm Sci; 1997 Dec; 86(12):1504-5. PubMed ID: 9423170
    [No Abstract]   [Full Text] [Related]  

  • 3. Optimal sampling times in bioequivalence tests.
    Kong FH; Gonin R
    J Biopharm Stat; 2000 Feb; 10(1):31-44. PubMed ID: 10709799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cmax/AUC is a clearer measure than Cmax for absorption rates in investigations of bioequivalence.
    Endrenyi L; Fritsch S; Yan W
    Int J Clin Pharmacol Ther Toxicol; 1991 Oct; 29(10):394-9. PubMed ID: 1748540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Choice of characteristics and their bioequivalence ranges for the comparison of absorption rates of immediate-release drug formulations.
    Schall R; Luus HG; Steinijans VW; Hauschke D
    Int J Clin Pharmacol Ther; 1994 Jul; 32(7):323-8. PubMed ID: 7952792
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of multiple-dose bioequivalence studies.
    Chinchilli VM; Esinhart JD; Barr WH
    J Biopharm Stat; 1994 Nov; 4(3):423-35. PubMed ID: 7881454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A limited sampling approach in bioequivalence studies: application to long half-life drugs and replicate design studies.
    Mahmood I; Mahayni H
    Int J Clin Pharmacol Ther; 1999 Jun; 37(6):275-81. PubMed ID: 10395118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic analysis of bioequivalence trials: implications for sex-related issues in clinical pharmacology and biopharmaceutics.
    Chen ML; Lee SC; Ng MJ; Schuirmann DJ; Lesko LJ; Williams RL
    Clin Pharmacol Ther; 2000 Nov; 68(5):510-21. PubMed ID: 11103754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and bioequivalence evaluation of 2 levosulpiride preparations after a single oral dose in healthy male Korean volunteers.
    Cho HY; Moon JD; Lee YB
    Int J Clin Pharmacol Ther; 2004 Mar; 42(3):174-80. PubMed ID: 15049438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. On the determination of bioequivalence.
    Farolfi M; Powers JD; Rescigno A
    Pharmacol Res; 1999 Jan; 39(1):1-4. PubMed ID: 10051371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An adjusted two one-sided t-test for the assessment of bioequivalence with multiple doses.
    Wang W; Hsuan F; Chow SC
    J Biopharm Stat; 1997 Mar; 7(1):157-70. PubMed ID: 9056595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cmax/AUC, a commentary.
    Tozer TN; Hauck WW
    Pharm Res; 1997 Aug; 14(8):967-8. PubMed ID: 9279874
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative pharmacokinetics and bioequivalence of two 50 mg atenolol tablet formulations in healthy Korean male volunteers.
    Chang MJ; Shin WG
    Arzneimittelforschung; 2012 Sep; 62(9):410-3. PubMed ID: 22791245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and bioequivalence study of a fixed dose combination of rabeprazole and itopride in healthy Indian volunteers.
    Sahoo BK; Das A; Agarwal S; Bhaumik U; Bose A; Ghosh D; Roy B; Pal TK
    Arzneimittelforschung; 2009; 59(9):451-4. PubMed ID: 19856792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence review for drug interchangeability.
    Chow SC; Shao J
    J Biopharm Stat; 1999 Aug; 9(3):485-97. PubMed ID: 10473033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers.
    Tian Y; Zhang JJ; Feng SD; Zhang ZJ; Chen Y
    Arzneimittelforschung; 2008; 58(10):497-500. PubMed ID: 19025058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The basis for individual bioequivalence. FDA Population and Individual Bioequivalence Working Group.
    Williams RL; Patnaik RN; Chen ML
    Eur J Drug Metab Pharmacokinet; 2000; 25(1):13-7. PubMed ID: 11032083
    [No Abstract]   [Full Text] [Related]  

  • 18. Secondary metrics for the assessment of bioequivalence.
    Endrenyi L; Tothfalusi L
    J Pharm Sci; 1997 Mar; 86(3):401-2. PubMed ID: 9050814
    [No Abstract]   [Full Text] [Related]  

  • 19. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group.
    Patnaik RN; Lesko LJ; Chen ML; Williams RL
    Clin Pharmacokinet; 1997 Jul; 33(1):1-6. PubMed ID: 9250419
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.